Psomagen Wins Additional ₩5B Project for Cell Analysis from Zuckerberg Foundation
Predicted impact: Medium
Additional ₩5B order, about 13% of revenue, but similar order already reported.
Psomagen소마젠
950200 · KOSDAQ · ₩950200 · 소마젠
₩2,965▲ ₩130 (4.59%)End-of-day · Oct 28, 2026 · End-of-day prices.
Price · 1Y −18.21%
- Market cap
- ₩57B
- Enterprise value
- ₩57B
- P/E
- 29,077.4×
- P/B
- 2,751.5×
- Dividend yield
- 0.0%
- ROE
- 9.5%
- Net margin
- 5.3%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−36.8% from the high
₩2,380Today: ₩2,810 – ₩3,600₩4,690
Returns
- 1W−1.7%
- 1M−4.4%
- 3M+12.3%
- 6M−20.6%
- YTD−23.6%
- 1Y−18.2%
- Volume today
- 504,454
- 8.8× the 20-day average
- Traded today
- ₩1.5B
- Listed shares
- 19,236,053
- EPS (12 months)
- ₩0
- Earnings yield 0.0%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Why is it moving?
+4.6% on Oct 28, 2026. Trading value 8.9× its normal.
Psomagen, a Korean genetic sequencing company, won an extra project worth about 5 billion won from a Zuckerberg-linked foundation to analyse cells. A separate report says the work is part of the Billion Cells Project and adds about $3.72 million.
AI summary of the news and filings linked. It can be wrong; check them.
- • Foreign investors sold a net ₩26M that day
- • Buzz 74 on JONBUR: heavy trading
Possible reasons, not certainties. Not financial advice.
Signals
Buzzing- BuzzHighBuzz 74: heavy trading.
- SentimentPositiveNews: Two news reports describe a new contract win. Community: 0 bullish, 0 bearish posts this week.
- MomentumFlat-4.8% over the last month; the price is below its 20-day average.
- News impactHigh2 news items and filings in two weeks; 1 rated high impact, 1 medium.
Signals describe activity, not recommendations. Not financial advice.
Psomagen stock overview
Psomagen (소마젠, KRX: 950200) is listed on KOSDAQ, in the Business services sector. Somagen is a Korean-listed company whose core business is genome sequencing services, primarily sold on a B2B basis to government agencies, universities and research centers, pharmaceutical companies and biotech firms in North America, with a clinical-grade presence in the United States. Its shares closed at ₩2,965 on Oct 28, 2026, up 4.59% on the day, giving it a market value of ₩57B.
Key facts
- Market cap
- ₩57B
- Sector
- Business services
- Latest price change
- +4.59%
- As of
- Oct 28, 2026
- Main business
- Somagen is a Korean-listed company whose core business is genome sequencing services, primarily sold on a B2B basis to government agencies, universities and research centers, pharmaceutical companies and biotech firms in North America, with a clinical-grade presence in the United States.
Quick answers about Psomagen
- What does Psomagen do?
- Somagen is a Korean-listed company whose core business is genome sequencing services, primarily sold on a B2B basis to government agencies, universities and research centers, pharmaceutical companies and biotech firms in North America, with a clinical-grade presence in the United States. com site and other channels.
- What is the market cap of Psomagen?
- The market capitalisation of Psomagen was ₩57B at the close on Oct 28, 2026.
- Who are the largest shareholders of Psomagen?
- According to the latest official filings, the largest reported holders are Macrogen (56.34%, as of Nov 6, 2025); Seo Jeong-seon (0.33%, as of Jan 3, 2025).
- When is the next earnings report from Psomagen?
- Korean companies rarely announce results dates in advance. Based on when Psomagen filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
Somagen is a Korean-listed company whose core business is genome sequencing services, primarily sold on a B2B basis to government agencies, universities and research centers, pharmaceutical companies and biotech firms in North America, with a clinical-grade presence in the United States. Its services span Sanger sequencing (CES), next-generation sequencing (NGS) including short-read and long-read platforms, single-cell analysis, proteomics, clinical genomic testing, and direct-to-consumer genetic and microbiome tests sold through its keanhealth.com site and other channels.
Written by AI from the company's latest annual report.
- Korean name
- 소마젠
- Sector
- Business services
- Themes
- AI healthcare
- CEO
- 홍수
- Founded
- Dec 2004
- Listed
- Jul 2020
- Listed shares
- 19,236,053
- Fiscal year ends
- Month 12
- Website
- psomagen.com
Similar companies
- S-1012750 · ₩3.6T₩95,100−0.21%
- Cheil Worldwide030000 · ₩2.1T₩18,510−2.63%
- Doosan Tesna131970 · ₩2T₩105,500+8.65%
- Lotte Tour Development032350 · ₩844B₩10,590+2.82%
- Soulbrain Holdings036830 · ₩791B₩38,600+2.52%
- Innocean Worldwide214320 · ₩702B₩17,560+1.15%
- Korea Ratings034950 · ₩456B₩100,500−0.30%
- Hanatour Service039130 · ₩436B₩28,150+3.87%
Recent news
Psomagen Adds $3.72M from CZI's Billion Cells Project, Demonstrating Single-Cell Analysis Capabilities
High impactPredicted impact: High
Added $3.72M order, about 13-15% of last year's revenue.
Recent filings
See all- Half-year report (Jun 2026)Aug 14, 2026
- Major management matter relevant to investorsJun 30, 2026
- Quarterly report (Mar 2026)May 15, 2026
- Annual general meeting resultsMar 31, 2026
- Amended: Notice of shareholders' meetingMar 24, 2026
Titles in Korean until English translations are added.
Also known as: Psomagen / 소마젠 / 950200 / KRX:950200
Source: KRX statistical information